HomeCompareCERC vs BTI

CERC vs BTI: Dividend Comparison 2026

CERC yields 68.26% · BTI yields 5.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CERC wins by $931.1K in total portfolio value
10 years
CERC
CERC
● Live price
68.26%
Share price
$2.93
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$968.9K
Annual income
$249,593.79
Full CERC calculator →
BTI
BTI
● Live price
5.40%
Share price
$58.26
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.8K
Annual income
$2,802.29
Full BTI calculator →

Portfolio growth — CERC vs BTI

📍 CERC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCERCBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CERC + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CERC pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CERC
Annual income on $10K today (after 15% tax)
$5,802.05/yr
After 10yr DRIP, annual income (after tax)
$212,154.72/yr
BTI
Annual income on $10K today (after 15% tax)
$459.05/yr
After 10yr DRIP, annual income (after tax)
$2,381.95/yr
At 15% tax rate, CERC beats the other by $209,772.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CERC + BTI for your $10,000?

CERC: 50%BTI: 50%
100% BTI50/50100% CERC
Portfolio after 10yr
$503.3K
Annual income
$126,198.03/yr
Blended yield
25.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

CERC
Analyst Ratings
5
Buy
1
Hold
Consensus: Buy
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.3% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CERC buys
0
BTI buys
0
No recent congressional trades found for CERC or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCERCBTI
Forward yield68.26%5.40%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$968.9K$37.8K
Annual income after 10y$249,593.79$2,802.29
Total dividends collected$822.0K$14.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: CERC vs BTI ($10,000, DRIP)

YearCERC PortfolioCERC Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$17,526$6,825.94$11,301$601.08+$6.2KCERC
2$29,933$11,180.47$12,799$706.58+$17.1KCERC
3$49,875$17,846.30$14,527$832.38+$35.3KCERC
4$81,156$27,790.26$16,527$982.75+$64.6KCERC
5$129,099$42,261.97$18,846$1,162.95+$110.3KCERC
6$200,966$62,830.03$21,545$1,379.49+$179.4KCERC
7$306,442$91,407.71$24,694$1,640.41+$281.7KCERC
8$458,156$130,263.77$28,378$1,955.69+$429.8KCERC
9$672,242$182,014.41$32,702$2,337.79+$639.5KCERC
10$968,892$249,593.79$37,794$2,802.29+$931.1KCERC

CERC vs BTI: Complete Analysis 2026

CERCStock

Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare pediatric and orphan diseases. It develop therapies for the treatment of inherited metabolic disorders, such as CERC-801 and CERC-802, which completed the phase I clinical trial; and CERC-803. The company is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of autoimmune inflammatory diseases, such as adult onset stills disease and multiple myeloma; CERC-006, a dual mTOR inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody for the treatment of Pediatric-onset Crohn's diseases. In addition, it develops CERC-913, a protide nucleotide for the treatment of mitochondrial disorder; CERC-005, a monoclonal antibody to treat rare auto-inflammatory diseases; CERC-301 for the treatment of symptomatic Orthostatic Hypotension; and CERC-406 for the treatment of Parkinson's disease. Further, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.

Full CERC Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this CERC vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CERC vs SCHDCERC vs JEPICERC vs OCERC vs KOCERC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.